Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cytokinetics Inc (NASDAQ: CYTK) closed the day trading at $50.25 up 2.34% from the previous closing price of $49.10. In other words, the price has increased by $2.34 from its previous closing price. On the day, 1.76 million shares were traded. CYTK stock price reached its highest trading level at $51.11 during the session, while it also had its lowest trading level at $49.445.
Ratios:
For a better understanding of CYTK, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.28 and its Current Ratio is at 9.28.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on November 08, 2024, initiated with a Outperform rating and assigned the stock a target price of $80.
On August 13, 2024, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $85 to $60.
UBS Downgraded its Buy to Neutral on January 24, 2024, whereas the target price for the stock was revised from $61 to $92.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 25 ’24 when WENDELL WIERENGA bought 742 shares for $50.00 per share.
Blum Robert I sold 5,000 shares of CYTK for $252,750 on Nov 18 ’24. The President & CEO now owns 397,456 shares after completing the transaction at $50.55 per share. On Nov 18 ’24, another insider, ROBERT BLUM, who serves as the Officer of the company, bought 5,000 shares for $50.55 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 5930203648 and an Enterprise Value of 5826749440. For the stock, the TTM Price-to-Sale (P/S) ratio is 1896.93. Its current Enterprise Value per Revenue stands at 1810.112 whereas that against EBITDA is -11.399.
Stock Price History:
Over the past 52 weeks, CYTK has reached a high of $110.25, while it has fallen to a 52-week low of $30.68. The 50-Day Moving Average of the stock is -6.02%, while the 200-Day Moving Average is calculated to be -15.19%.
Shares Statistics:
Over the past 3-months, CYTK traded about 1.23M shares per day on average, while over the past 10 days, CYTK traded about 1558590 shares per day. A total of 118.01M shares are outstanding, with a floating share count of 113.59M. Insiders hold about 3.75% of the company’s shares, while institutions hold 113.26% stake in the company. Shares short for CYTK as of 1730332800 were 15689835 with a Short Ratio of 12.80, compared to 1727654400 on 17322576. Therefore, it implies a Short% of Shares Outstanding of 15689835 and a Short% of Float of 20.31.
